Pulmonary arterial hypertension and chronic myeloproliferative disorders [3]

American Journal of Respiratory and Critical Care Medicine

Volumn 174, Issue 5, 2006, Pages 616-

  Di Stefano, Fabio ^a  

^a Presidio Ospedaliero G Bernabeo Azienda USL Chieti   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; JANUS KINASE 2; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; SEROTONIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE A2; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ARTERY EMBOLISM; CHRONIC DISEASE; DISEASE ASSOCIATION; ERYTHROBLASTOSIS; HUMAN; LETTER; LUNG ARTERY; LUNG EMBOLISM; LUNG VASOCONSTRICTION; MEDICAL SPECIALIST; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PULMONARY HYPERTENSION; THROMBOCYTE ACTIVATION; THROMBOCYTOSIS;

EID: 33748308766     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/ajrccm.174.5.616     Document Type: Letter

References (6)

1. Hoeper MM, Rubin LJ. Update in pulmonary hypertension 2005. Am J Respir Crit Care Med 2006;173:499-505.
2. Dingli D, Utz JP, Krowka MJ, Oberg AL, Tefferi A. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest 2001;120:801-808.
3. Ito H, Adachi Y, Arimura Y, Endo T, Hinoda Y, Imai K. A 25-year clinical history of portopulmonary hypertension associated with latent myeloproliferative disorder. J Gastroenterol 2003;38:488-492.
4. Acharya J, Westwood NB, Sawyer BM, Messinezy M, Burroughs AK, Mehta AB, Pearson TC. Identification of latent myeloproliferative disease in patients with Budd-Chiari syndrome using X-chromosome inactivation patterns and in vitro erythroid colony formation. Eur J Haematol 1995;55:315-321.
5. Michiels JJ. Clinical, pathological and molecular features of the chronic myeloproliferative disorders: MPD 2005 and beyond. Hematology (Am Soc Hematol Educ Program) 2005;10:215-223.
6. Michiels JJ, Berneman Z, Bockstaele DV, van der Planken M, De Raeve H, Schroyens W. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost 2006;32:174-207.